• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Edgewise

Edgewise Therapeutics

A Movement in Muscle

  • Clinical Trials
  • Careers
  • Investors & News
  • Company
    • Company Overview
    • Leadership Team
    • Careers
    • Contact Us

    Our vision is to improve the lives of patients and families suffering from serious muscle diseases by building the world’s leading muscle-focused company.

    Learn More

  • Science
    • Science Overview
    • Pipeline
    • Sevasemten
    • EDG-7500
    • EDG-15400
    • Clinical Trials
    • Posters & Presentations

    All of us at Edgewise are committed to developing new medicines for people facing serious muscle diseases with unmet medical needs.

    Explore our Science

  • Disease Areas
    • Disease Areas Overview
    • Muscular Dystrophy
    • Cardiovascular Diseases

    Learn more about how our science is driving a new understanding of muscle and its potential to transform human health.

    Explore Muscle

  • Patients & Families
    • Patients & Families Overview
    • Support for Becker
    • Support for Duchenne
    • Support for HCM
    • Patient Stories

    We honor the experience of individuals and families living with and facing the challenges of serious muscle disease.

    Read their Stories

  • Investors & News
    • Corporate Profile
    • News
    • Events & Presentations
    • Analyst Coverage
    • Stock Info
      • Stock Quote
      • Stock Chart
      • Historical Stock Quote
      • Investment Calculator
    • Financials
      • Quarterly Results
      • SEC Filings
    • Governance
      • Governance Documents
      • Committee Composition
    • Resources
      • Investor FAQs
      • Investor Email Alerts
      • Investor Contacts
Home Company Leadership Team Michael Nofi

Michael Nofi

Chief Financial Officer

Michael Nofi has served as our Chief Financial Officer since November 2025. Most recently Mr. Nofi served as Chief Accounting Officer of SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, where he led the company from its IPO, commercial transformation, and acquisition by Merck KGaA. Prior to SpringWorks, he was Chief Accounting Officer and Vice President of Global Accounting and Corporate FP&A at The Nature’s Bounty Co. Mr. Nofi also held senior finance roles at Acorda Therapeutics, Allergan plc, and Forest Laboratories, where he led integration efforts across multiple acquisitions. Earlier in his career, he served as a Senior Manager at PricewaterhouseCoopers, LLP. Mr. Nofi holds a B.S. in accounting and an M.B.A. from Villanova University and is a Certified Public Accountant.

  • Meet our leadership team
  • Meet our board of directors

Footer

Edgewise Therapeutics
  • Disease Areas
  • Science
  • Patients & Families
  • Company
  • Investors & News

In the Clinic

We are advancing novel precision therapeutics for serious muscle disease.

Explore our pipeline

2025 © Copyright. Edgewise Therapeutics. All Rights Reserved.

  • Privacy Policy
  • Terms of Use
Facebook X, formally Twitter LinkedIn Instagram YouTube
logo
  • Company
    • Leadership Team
    • Careers
    • Contact Us
  • Science
    • Pipeline
    • Sevasemten
    • EDG-7500
    • EDG-15400
    • Clinical Trials
    • Posters & Presentations
  • Disease Areas
    • Muscular Dystrophy
    • Cardiovascular Diseases
  • Patients & Families
    • Support for Becker
    • Support for Duchenne
    • Support for HCM
    • Patient Stories
  • Investors & Media
    • Corporate Profile
    • News
    • Events & Presentations
    • Analyst Coverage
    • Stock Info
      • Stock Quote
      • Stock Chart
      • Historical Stock Quote
      • Investment Calculator
    • Financials
      • Quarterly Results
      • SEC Filings
    • Goverance
      • Governance Documents
      • Committee Composition
    • Resources
      • Investor FAQs
      • Investor Email Alerts
      • Investor Contacts